debrisoquin has been researched along with Bladder Cancer in 7 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Debrisoquine, mephenytoin, and dapsone were used as in vivo probes for the activities of P4502D6, 2CMP, and 3A4, respectively, as well as dapsone for N-acetyltransferase, in order to assess the relationship between such activities and the relative risk of recurrence of bladder cancer." | 7.68 | The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. ( Branch, RA; Fleming, CM; Kaisary, A; Smith, P; Wilkinson, GR, 1992) |
| "The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96." | 7.68 | Polymorphic oxidation of debrisoquine in bladder cancer. ( Benítez, J; Cobaleda, J; Fernández-Gundín, MJ; González-Rozas, F; Ladero, JM; Llerena, A; Martínez, C; Muñoz, JJ; Prados, J; Vargas, E, 1990) |
| "A report is given of a series of bladder cancer cases examined for the oxidation capacity demonstrated by the use of debrisoquine." | 7.67 | Genetically determined debrisoquine oxidation capacity in bladder cancer. ( Cartwright, RA; Glashan, RW; Philip, PA; Rogers, HJ, 1984) |
| "Patients with bladder cancer were classified on histological criteria as having aggressive (Stage III) (34%) or nonaggressive (Stages I and II) (66%) disease." | 5.27 | Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. ( Branch, RA; Jaczq, E; Kaisary, A; McAllister, CB; Ray, WA; Smith, P; Wilkinson, GR, 1987) |
| "Debrisoquine hydroxylase activity has been attributed to CYP2D6 and poor metabolizers of debrisoquine have a reduced relative risk of developing aggressive bladder cancer." | 3.69 | Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. ( Branch, RA; Chern, HD; Fleming, C; Mnuskin, A; Persad, R; Romkes-Sparks, M; Sibley, GN; Smith, P; Wilkinson, GR, 1994) |
| " Debrisoquine, mephenytoin, and dapsone were used as in vivo probes for the activities of P4502D6, 2CMP, and 3A4, respectively, as well as dapsone for N-acetyltransferase, in order to assess the relationship between such activities and the relative risk of recurrence of bladder cancer." | 3.68 | The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. ( Branch, RA; Fleming, CM; Kaisary, A; Smith, P; Wilkinson, GR, 1992) |
| " Three examples of pharmacogenetic risk factors are discussed: the first two are p450 enzymes whose activity has been associated with susceptibility to lung cancer (debrisoquine hydroxylase, aryl hydrocarbon hydroxylase), and the last, N-acetyltransferase, a non-p450 enzyme, has been associated with bladder cancer susceptibility." | 3.68 | Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens. ( Caporaso, N, 1991) |
| "The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96." | 3.68 | Polymorphic oxidation of debrisoquine in bladder cancer. ( Benítez, J; Cobaleda, J; Fernández-Gundín, MJ; González-Rozas, F; Ladero, JM; Llerena, A; Martínez, C; Muñoz, JJ; Prados, J; Vargas, E, 1990) |
| "A report is given of a series of bladder cancer cases examined for the oxidation capacity demonstrated by the use of debrisoquine." | 3.67 | Genetically determined debrisoquine oxidation capacity in bladder cancer. ( Cartwright, RA; Glashan, RW; Philip, PA; Rogers, HJ, 1984) |
| "Patients with bladder cancer were classified on histological criteria as having aggressive (Stage III) (34%) or nonaggressive (Stages I and II) (66%) disease." | 1.27 | Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. ( Branch, RA; Jaczq, E; Kaisary, A; McAllister, CB; Ray, WA; Smith, P; Wilkinson, GR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cartwright, RA | 1 |
| Philip, PA | 1 |
| Rogers, HJ | 1 |
| Glashan, RW | 1 |
| Romkes-Sparks, M | 1 |
| Mnuskin, A | 1 |
| Chern, HD | 1 |
| Persad, R | 1 |
| Fleming, C | 1 |
| Sibley, GN | 1 |
| Smith, P | 3 |
| Wilkinson, GR | 3 |
| Branch, RA | 3 |
| Fleming, CM | 1 |
| Kaisary, A | 2 |
| Pelkonen, O | 1 |
| Caporaso, N | 1 |
| Benítez, J | 1 |
| Ladero, JM | 1 |
| Fernández-Gundín, MJ | 1 |
| Llerena, A | 1 |
| Cobaleda, J | 1 |
| Martínez, C | 1 |
| Muñoz, JJ | 1 |
| Vargas, E | 1 |
| Prados, J | 1 |
| González-Rozas, F | 1 |
| Jaczq, E | 1 |
| McAllister, CB | 1 |
| Ray, WA | 1 |
1 review available for debrisoquin and Bladder Cancer
| Article | Year |
|---|---|
Carcinogen metabolism and individual susceptibility.
Topics: Acetylation; Animals; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carcinogens; Debrisoquin; Forecasti | 1992 |
6 other studies available for debrisoquin and Bladder Cancer
| Article | Year |
|---|---|
Genetically determined debrisoquine oxidation capacity in bladder cancer.
Topics: Benzidines; Debrisoquin; Humans; Isoquinolines; Occupational Diseases; Oxidation-Reduction; Urinary | 1984 |
Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Topics: Base Sequence; Case-Control Studies; Cystoscopy; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Sy | 1994 |
The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer.
Topics: Aged; Biotransformation; Carcinogens, Environmental; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzym | 1992 |
Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Topics: Biotransformation; Carcinogens, Environmental; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytoch | 1991 |
Polymorphic oxidation of debrisoquine in bladder cancer.
Topics: Aged; Alcohol Drinking; Carcinoma, Transitional Cell; Debrisoquin; Female; Humans; Isoquinolines; Ma | 1990 |
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Topics: Acetylation; Aged; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytoch | 1987 |